Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose

13Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Background:We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent to which a person's fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer's disease (AD). Apolipoprotein E ε4 (APOE ε4) gene dose is associated with three levels of risk for late-onset AD. We explored the association between gene dose and HCI in cognitively normal ε4 homozygotes, heterozygotes, and non-carriers.Methods:An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including 36 ε4 homozygotes, 46 heterozygotes, and 78 non-carriers.Results:These three groups differed significantly in their HCIs (ANOVA, p = 0.004), and there was a significant association between HCIs and gene dose (linear trend, p = 0.001).Conclusions:The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a single FDG PET measurement to help in the preclinical detection and tracking of AD. © 2013 Schraml et al.

Cite

CITATION STYLE

APA

Schraml, F., Chen, K., Ayutyanont, N., Auttawut, R., Langbaum, J. B. S., Lee, W., … Reiman, E. M. (2013). Association between an Alzheimer’s Disease-Related Index and APOE ε4 Gene Dose. PLoS ONE, 8(6). https://doi.org/10.1371/journal.pone.0067163

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free